Elekta AB (publ) (OTCMKTS:EKTAY – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It […]
Elekta AB (publ) (OTCMKTS:EKTAY – Get Rating) and Sera Prognostics (NASDAQ:SERA – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Institutional and Insider Ownership 46.7% of Sera Prognostics shares […]
Elekta AB (publ) (OTCMKTS:EKTAY – Get Rating) – Stock analysts at Jefferies Financial Group reduced their FY2022 EPS estimates for Elekta AB (publ) in a research note issued on Monday, March 7th. Jefferies Financial Group analyst M. Toomey now anticipates that the company will post earnings per share of $0.30 for the year, down from […]